News Releases

Summary Toggle Teligent, Inc. Announces FDA Approval of Partnered ANDA for Desonide Lotion, 0.05%

BUENA, N.J. , Oct. 02, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s partnered abbreviated new drug application (ANDA) from the U.S.

October 2, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Triamcinolone Acetonide Cream USP, 0.1%

BUENA, N.J. , Sept. 19, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

September 19, 2017

PDF Version
Summary Toggle Teligent, Inc. Appoints Thomas J. Sabatino, Jr. to Board of Directors

BUENA, N.J. , Sept. 18, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has appointed Thomas J. Sabatino, Jr. to its Board of Directors. Mr. Sabatino will also serve on the Company’s Audit Committee. Jason

September 18, 2017

PDF Version
Summary Toggle Teligent, Inc. to Present at Morgan Stanley 15th Annual Global Healthcare Conference on September 12, 2017

BUENA, N.J. , Sept. 12, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Morgan Stanley 15th Annual Global Healthcare Conference. The Conference is taking place September 11-13, 2017 at the Grand Hyatt

September 12, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval of Clobetasol Propionate Cream USP, 0.05%, Emollient

BUENA, N.J. , Aug. 22, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug application (ANDA) from the U.S.

August 22, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces Second Quarter 2017 Results

BUENA, N.J. , Aug. 08, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced its financial results for the second quarter ended June 30, 2017 . Second Quarter 2017 Highlights Total revenues of $18.4 million in the second

August 8, 2017

PDF Version
Summary Toggle Teligent, Inc. to Hold Conference Call for Second Quarter 2017 Results

BUENA, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday, August 8, 2017 to discuss the 2nd quarter 2017 financial results and business

July 28, 2017

PDF Version
Summary Toggle Teligent, Inc. Announces FDA Approval Of Erythromycin Topical Gel USP, 2%

BUENA, N.J. , July 21, 2017 /PRNewswire/ -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey -based specialty generic pharmaceutical company, today announced it has received approval of the Company's abbreviated new drug application (ANDA) from the U.S. Food and Drug Administration ( FDA ) of

July 21, 2017

PDF Version
Summary Toggle Teligent, Inc. To Present At Bank Of America Merrill Lynch Healthcare Conference Taking Place May 16, 2017

UENA, N.J., May 16, 2017 / PRNewswire / -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at Bank of America Merrill Lynch Healthcare Conference taking place on May 16-18, 2017 at Encore at Wynn Las

May 16, 2017

PDF Version
Summary Toggle Teligent, Inc. To Present At Deutsche Bank 42nd Annual Health Care Conference On May 3, 2017

BUENA, N.J., May 3, 2017 / PRNewswire / -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey based specialty generic pharmaceutical company, will be presenting at the Deutsche Bank 42 nd Annual Health Care Conference. The Conference is taking place on May 3-4, 2017 at

May 3, 2017

PDF Version